一種新型設(shè)備被設(shè)計用于防止充血性心衰患者在接受冠狀動脈手術(shù)的時候出現(xiàn)腎功能不全。

慢性腎臟疾病合并充血性心衰會增加由于血管造影術(shù)中使用的染料或者支架手術(shù)時候發(fā)生腎臟功能衰竭的危險。這套Benephit Delta系統(tǒng)是以導(dǎo)管為基礎(chǔ)的醫(yī)療設(shè)備，能夠?qū)⑻囟ㄋ幬锖推渌委熕幬镏苯虞斔偷侥I動脈。系統(tǒng)能夠?qū)筛I動脈同時進(jìn)行選擇性給藥，而只需使用一根導(dǎo)管。設(shè)計這套系統(tǒng)的主要目的是進(jìn)行靶向腎臟治療，作為系統(tǒng)性靜脈注射藥物治療充血性心衰相關(guān)腎臟功能不全的替代選擇。

近期在美國NewYork-Presbyterian醫(yī)院一例男性患者中進(jìn)行了這種操作程序，該患者當(dāng)時接受血管擴(kuò)張手術(shù)以治療冠狀動脈重度阻塞。在他的冠狀動脈中放置了5個支架，這需要使用大劑量的染料。手術(shù)中使用Benephit Delta系統(tǒng)將一種藥物 (非諾多泮)通過腎臟動脈直接輸送到患者的腎臟，以增加血流量。患者沒有出現(xiàn)危及生命的放射造影劑腎病。心血管醫(yī)生估計大約有20％接受冠狀動脈干預(yù)手術(shù)的患者能夠從對放射造影劑腎病的治療中獲益。

Benefit Delta系統(tǒng)是由美國FlowMedica公司研制開發(fā)的，這是一家醫(yī)療設(shè)備公司。

Device Helps Prevent Kidney Dysfunction
 
A new device is designed to help prevent kidney dysfunction in patients with congestive heart failure (CHF) while undergoing coronary procedures.

The combination of chronic kidney disease and CHF greatly increases a patient’s risk of developing kidney failure from the dye used during an angiography or stenting procedure. The Benephit Delta system is a catheter-based medical device that enables the administration of specified medications and other therapeutic agents directly to the renal arteries. The system can provide selective infusion to both renal arteries simultaneously, using a single catheter. It is designed to provide targeted renal therapy (TRT), an alternative to systemic intravenous infusion of medications to treat kidney dysfunction related to CHF.

The procedure was recently used on a male patient at NewYork-Presbyterian Hospital (NY, USA) who had recently had angioplasty to treat two severely blocked coronary arteries. Five stents were placed in his coronary arteries, which required large amounts of dye. The Benephit Delta system was used to deliver a medication (fenoldopam) directly into the patient’s kidneys through the renal arteries to increase blood flow. The patient did not develop the potentially life-threatening condition known as radiocontrast nephropathy (RCN). Cardiologists estimate that about 20% of patients undergoing coronary interventions could benefit from treatment for RCN.

The Benefit Delta system was developed by FlowMedica, a medical device company (Fremont, CA, USA).